Zacks Investment Research upgraded shares of Ritter Pharmaceuticals Inc (NASDAQ:RTTR) from a sell rating to a hold rating in a report published on Wednesday.
According to Zacks, “Ritter Pharmaceuticals, Inc. is involved in developing therapeutic products to treat inflammatory, gastrointestinal and metabolic diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. Ritter Pharmaceuticals, Inc. is headquartered in Los Angeles, California. “
Other equities research analysts have also recently issued reports about the stock. Chardan Capital raised their price target on shares of Ritter Pharmaceuticals from $3.00 to $3.30 and gave the stock a buy rating in a research note on Tuesday, October 25th. Aegis reaffirmed a buy rating and set a $9.00 price target on shares of Ritter Pharmaceuticals in a research note on Tuesday, October 18th. Finally, Maxim Group reissued a buy rating on shares of Ritter Pharmaceuticals in a research report on Monday, October 17th.
Ritter Pharmaceuticals (NASDAQ:RTTR) opened at 2.38 on Wednesday. The firm’s 50-day moving average is $1.92 and its 200 day moving average is $1.63. Ritter Pharmaceuticals has a 12-month low of $0.98 and a 12-month high of $3.26. The firm’s market cap is $20.43 million.
Ritter Pharmaceuticals (NASDAQ:RTTR) last released its quarterly earnings results on Monday, August 8th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by $0.14. Equities research analysts predict that Ritter Pharmaceuticals will post ($1.80) EPS for the current year.
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.